Skip to main content

Menu

BNF for Children February 2024 Update

This update contains 6 significant changes, 1 dose change, 1 new monograph, and 3 deleted monographs.

Significant Changes:

  • Baclofen: update to expression of doses for chronic severe spasticity of voluntary muscle.
  • Controlled drugs and drug dependence: control of nitrous oxide.
  • Insulin degludec (Tresiba®): potential for inappropriate dosing of insulin when switching Tresiba® products [National Patient Safety Alert advice].
  • Liraglutide (Saxenda®): vigilance required due to potentially harmful falsified products [MHRA/CHM advice].
  • Semaglutide (Ozempic®): vigilance required due to potentially harmful falsified products [MHRA/CHM advice].
  • Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients [National Patient Safety Alert advice] (advice in sodium valproate, valproic acid; see example in sodium valproate).

Dose Changes:

  • Octasa® MR 400 mg and 800 mg tablets (mesalazine).

New Monographs:

  • Slynd® [drospirenone].

Deleted Monographs: Diflucortolone valerate; Fluocinolone acetonide with clioquinol; Fluocinolone acetonide with neomycin.